

Your Vision, Our Future

Olympus Group Financial Results for the 2nd Quarter of the Fiscal Year Ending March 31, 2014

Hiroyuki Sasa President and Representative Director Olympus Corporation

November 8, 2013

2Q Highlights

[Operating Environment]

- Global economy: Gentle recovery trend evident, but conditions unclear in Europe, amid sovereign debt crisis, as well as in China and other emerging markets
- Japanese economy: Perception of economic improvement due to yen depreciation and full-fledged recovery expected going forward

I. Consolidated Results: Substantially higher operating income driven by strong performance in Medical Business

II. Medical Business: Steady progress in implementation of strategies of medium-term vision (corporate strategic plan)

III. Imaging Business: Accelerated shift to mirrorless cameras

IV. Financial position: Significant improvement in equity ratio

I. Consolidated Financial Results for the 2Q of Fiscal 2014

- Consolidated results supported by strong performance in Medical Business, and operating income up YOY and higher than forecast
- Provision for loss on litigation of ¥17 billion recorded as extraordinary loss in consideration of lawsuit proceedings

(Billions of yen)	Fiscal 2013 2Q (Apr-Sept)	Fiscal 2014 2Q (Apr-Sept) (Forecast as of Aug. 2013)	Fiscal 2014 2Q (Apr-Sept)	ΥοΥ	Compared to forecast
Net sales	405.8	335.0	333.8	-18%	0%
Operating income (% of sales)	18.0 (4.4%)	27.0 (8.1%)	28.5 (8.5%)	+58%	+6%
Ordinary income	7.4	17.5	17.0	+129%	-3%
Net income	8.0	10.0	-7.9		

II. Medical: Steady Progress in Implementation of Strategies of Medium-term Vision

Achieved record-breaking 1st half net sales owing to introduction of new, flagship products

Actively invested and operated in growth fields to achieve goals of medium-term vision

Expand sales in emerging markets

 Established training center in Guangzhou, 4th base in China, in conjunction with medical operations growth in China, and strengthen service systems by jointly establishing major repair center

Realize rapid growth in surgical field

 Strengthen marketing and sales systems centered on developed nations to further growth in surgical and endotherapy field



(Facade of Guangzhou Training Center)

 Introduced new energy device THUNDERBEAT into Japan ahead of schedule in October (already introduced into Europe and Americas), and strengthen related sales systems in Japan to respond to high market evaluation

III. Imaging Business: Accelerated Shift to Mirrorless Cameras

Factors Preventing Accomplishment of Forecasts in 1st Half

Operating loss recorded due to failure to accomplish sales targets and yen depreciation

[Income / Loss in 1st Half]

(Billions of yen)	FY2013 1H (Results)	FY2014 1H (Forecast)	FY2014 1H (Results)	Change (Compared to forecast)
Net sales	55.9	53.0	47.0	-6.0
Compact camera	30.9	25.0	22.7	-2.3
SLR(mirrorless)	18.8	21.5	18.2	-3.3
Others(IC recorder)	6.2	6.5	6.2	-0.3
Gross margin	22.5	22.0	22.1	+0.1
SG&A expenses	27.0	22.0	24.8	+2.8
Operating income/loss	-4.4	0	-2.7	-2.7

[Compact]

Sales volumes in line with forecasts, but failed to meet sales targets due to unexpected degree of drops in selling prices

[Mirrorless]

 Introduction of new PEN series products delayed

•Shift in sales system toward mirrorless partially delayed until the 2nd half

Gross profit increased due to efforts to reduce cost of sales

SG&A expenses increased due to impacts of yen depreciation, but cost-cutting measures advanced as planned

Progress of Restructuring the Business (1) Risk Minimization


- i. Minimize risks in compact camera operations
 - Ceased development of low-priced compact cameras
 - ✓ Substantially reduced number of new fall 2013 model compact cameras

ii. Focus resources on high-margin mirrorless cameras

- Concentrated manufacturing and development resources on mirrorless cameras
- Shifted marketing and sales activities toward mirrorless cameras

iii. Improve responsiveness to market changes

- ✓ Reduced inventories more than planned through strengthened monitoring (cut inventories of older products by 75%)
- ✓ Reduced compact camera inventory by 40% from March 31, 2013, on unit basis



Progress of Restructuring the Business (2)

Construct cost structure appropriate for business scale

Reorganize manufacturing systems:

Completed consolidation of 5 sites into 2 (Shenzhen and Vietnam)

Staff reductions:

Reduced staff* by 30% from March 31, 2012, focused on manufacturing, development, and sales

Reorganize sales systems:

Advanced integration of overseas sales systems centered on Europe and Americas

✓ Europe: Completed consolidation of approx. 20 sites into 7


✓ Americas: Made the shift from direct sales to agency in Latin America Reductions in costs:

Achieved approx. 50% of full fiscal year's total cost reduction target of ¥23 billion in manufacturing costs and SG&A expenses during 1st half

Accelerated Shift to Mirrorless Cameras (1)

OM-D E-M1—New Product Highly Evaluated Worldwide

Received highest score for a digital camera in major German photography magazine "fotoMAGAZIN"*



*Olympus' OM-D E-M1 was the only product to receive a total score of more than 90% among all cameras on the market, including full-sized cameras from other manufacturers. (Source: "fotoMAGAZIN, November")

[High Evaluations from Other Countries]

- Presented Gold Award by major digital camera reviewer "DP Review"
- Named "Best Camera of the Year" and "Best High-End Mirrorless Camera" for fiscal 2013 by major U.S. reviewer "Reviewed.Com"
- Awarded five stars with high praise for resolution and performance by French specialty magazine "Chasseur d'Images"
- <u>Received "Editors Choice Award"</u> from The Straits Times, Singapore's largest English-language newspaper

Accelerated Shift to Mirrorless Cameras (2)

Develop business structure centered on mirrorless cameras, and transition to earnings structures capable of generating a profit

Continue strengthening monitoring to better manage progress in implementing initiatives

[Forecast of 2n	d Half]			[Compact]
(Billions of yen)	FY2013 2H (Results)	FY2014 2H (Forecast)	YoY Change	Sales volumes down 50% on unit basis (Substantial contraction of compact camera business) [Mirrorless]
Net sales	51.7	57.0	+5.3	 New product in OM-D series (E-M1) highly praised in growing mirrorless camera market and to contribute to
Compact camera	26.3	15.9	-10.4	sales growthFurther expansion of OM-D series system planned for 2H
SLR (mirrorless)	19.0	33.9	+14.9	•2H sales volume target: 410,000 units (+41% YOY)
Others(IC recorder)	6.3	7.2	+0.9	Gross profit to increase due to efforts to reduce cost of sales
Gross margin	10.1	22.6	+12.5	(Ratio of mirrorless to net sales: $37\% \rightarrow 58\%$)
SG&A expenses	28.7	24.8	-3.9	Rise in SG&A expenses due to yen depreciation to be absorbed by cost-cutting measures
Operating income/loss	-18.6	-2.3	+16.3	Transition to earnings structures capable of generating a profit by shifting to mirrorless cameras

Copyright Olympus Corporation





Your Vision, Our Future

Consolidated Financial Results for the 2nd Quarter of the Fiscal Year Ending March 31, 2014 and the Full-year Forecast

Yasuo Takeuchi

Director, Senior Executive Managing Officer Group President of Group Management Office Olympus Corporation

November 8, 2014

(1) Consolidated Financial Results and Overview by Segment for 2Q of the FY2014

2Q of FY2014 (YoY) - (1)Consolidated Financial Results

(Billions of yen)	FY2013 1H (Apr-Sep)	FY2014 1H (Apr-Sep)	YoY Change	YoY (%)	FY2013 2Q (Jul-Sep)	FY2014 2Q (Jul-Sep)	YoY (%)
Net sales	405.8	333.8	-71.9	-18%	216.2	<mark>174.6</mark>	-19%
SG&A expenses (% to sales)	169.4 (41.8%)	176.4 (52.9%)	+7.0 (+ 11.1pt)	+4%	84.9 (39.2%)	<mark>90.4</mark> (51.8%)	+7%
Operating income (% to sales)	18.0 (4.4%)	28.5 (8.5%)	+10.5 (+ 4.1pt)	+58%	15.9 (7.4%)	<mark>20.3</mark> (11.6%)	+28%
Ordinary income (% to sales)	7.4 (1.8%)	17.0 (5.1%)	+9.6 (+ 3.3pt)	+129%	7.6 (3.5%)	<mark>14.6</mark> (8.3%)	+91%
Net income (% to sales)	8.0 (2.0%)	-7.9 (-)	-16.0 (-)	-	12.5 (5.8%)	-6.1 (-)	-
[Foreign exchange rat	tes and impact]						
¥/US\$	¥79	¥99	¥19(yen	depreciation)			
¥/Euro	¥101	¥130	¥29(yen	depreciation)			
Impact on net sales	-	+¥51.4 bil.					
Impact on Op. imcome	-	+¥10.2 bil.					

<u>1st Half</u> Key Points ✓ Achieved record-breaking 1st half net sales and operating income in Medical Business, which supported consolidated results with strong performance


Extraordinary loss: ¥17 billion in provision for loss on litigation

2Q of FY2014 (YoY) - (2) Results by Business Segment

(Billions of yen)	FY2013 1H (Apr-Sep)	FY2014 1H (Apr-Sep)	YoY Change	YoY change (%)
Medical	Net sales	176.2	229.8	+53.6	+30%
Medical	Op. income	37.4	49.2	+11.9	+32%
Life Science &	Net sales	38.1	44.0	+5.9	+15%
Industrial	Op. income	1.1	0.5	-0.5	-50%
Imaging	Net sales	55.9	47.0	-8.9	-16%
Imaging	Op. income	-4.4	-2.7	+1.7	-
Information &	Net sales	114.2	-	-114.2	-
Communication	Op. income	1.7	-	-1.7	-
Others	Net sales	21.3	13.0	-8.3	-39%
Others	Op. income	-3.6	-2.8	+0.8	-
Elimination and	Net sales	-	-	-	-
corporate	Op. income	-14.1	-15.7	-1.7	-
Consolidated	Net sales	405.8	333.8	-71.9	-18%
Total	Op. income	18.0	28.5	10.5	+58%

2Q of FY2014 (YoY) - (3) Medical Business


- Posted record-breaking 1st half net sales and operating income, with new products performing favorably
- Strategic investment accelerated to achieve goals of medium-term vision, but high profit margins maintained due to contributions from increased sales in highly profitable endoscope field



2Q of FY2014 (YoY) - (4) Life Science & Industrial Business


Sales up due to recovering domestic demand and benefits of new product sales

Operating income down due to investments in sales promotion to fuel future sales growth




2Q of FY2014 (YoY) - (5) Imaging Business

Sales down due to lower sales volumes of mirrorless cameras and compact cameras
 Operating loss improvements realized through cost reductions, but operating loss recorded due to lower net sales and increased expenses as result of foreign exchange rates (yen depreciation)



2Q of 2014 (YoY) - (6) Net Sales by Region (Core Three Businesses)

Sales up in all regions due to substantial contributions from strong performance of Medical (Growth of the Medical during Jul-Sep: Japan +21%, N.America +42%, Europe +25%, Asia/Oceania +30%)



Note: Graphs above are the total of core three businesses (Medical, Life Science & Industrial, and Imaging) 19

2Q of FY2014 (Comparison with Previous Forecast)

(7) Factors behind Operating Income Changes

Medical (+¥3.2 billion) : Operating income higher than forecast due to strong performance of new, high-margin products and benefits of foreign exchange rates

Life Science & Industrial (–¥1.0 billion) : Operating income lower than forecast because unfavorable macroeconomic conditions in Europe and Americas resulted in failure to meet sales targets

Imaging (-¥2.7 billion): Despite cost-cutting efforts, operating income lower than forecast due to reduced net sales (drop in compact camera selling prices and failure to meet mirrorless camera sales targets) and negative impacts of foreign exchange rates



Balance Sheet (End of September 2013)

 Reduction of approx. ¥130 billion in interest-bearing debt (from March 2013) and increase in capital of approx. ¥110 billion resulted in <u>13pt improvement in equity ratio</u> (from March 2013), to roughly 30%

Т

(Billions of yen)	End Mar 2013	End Sept 2013	Change		End Mar 2013	End Sept 2013	Change
Current assets (Digital camera inventories)	541.0 (23.6)	536.6 (24.5)	-4.4 (+0.9)	Current liabilities	316.9	260.0	-56.8
Property, plant and equipment	129.8	133.9	+4.1	Non-current liabilities (Incl. bonds/ long-term loans payable)	491.5 (422.9)	430.1 (355.8)	-61.4 (-67.0)
Intangible assets	174.6	172.5	-2.1	Net assets	151.9	280.6	+128.7
Investments and other assets	114.8	127.7	+12.9	(Equity ratio)	(15.5%)	(28.7%)	(+13.2pt)
Total assets	960.2	970.8	+10.5	Total liabilities and net assets	960.2	970.8	+10.5
Interest-bearing debt: ¥430.0 billion (-¥130.4 billion from March 2013) Net interest-bearing debt: ¥196.9 billion (-¥133.9 billion from March 2013)							

Cash Flows (April – September)

(E	Billions of yen)	FY2013 2Q (Apr-Sept)	FY2014 2Q (Apr-Sept)	Change
Ν	et sales	405.8	333.8	-71.9
0	perating income	18.0	28.5	+10.5
	(%)	4.4	8.5	4.1pt
	CF from operating activities	6.5	29.4	+22.9
	CF from investing activities	37.3	-10.7	-48.0
	CF from financing activities	-52.1	-21.9	+30.2
С	ash flow	-8.4	-3.2	+5.2
Free cash flow		43.7	18.7	-25.0
Cash and cash equivalents at end of year		186.0	229.0	+43.0

Depreciation and amortization	15.7	16.9	+1.2
Amortizaion of goodwill	5.4	4.7	-0.8
Capital expenditures	14.6	17.2	+2.6

(2) Forecasts for Fiscal 2014

Forecasts of Consolidated Financial Results for Fiscal 2014

(Billions of yen)	FY2013 Full-year (Results)	FY2014 Full-year (Current forecast)	YoY Change	YoY (%)	FY2014 Full-year (Previous forecast)
Net sales	743.9	720.0	-23.9	-3%	700.0
Operating income (% to net sales)	35.1 (4.7%)	72.5 (10.1%)	37.4 (+5.4pt)	+107%	71.0
Ordinary income (% to net sales)	13.0 (1.8%)	50.0 (6.9%)	37.0 (+5.1pt)	+283%	48.0
Net income (% to net sales)	8.0 (1.1%)	13.0 (1.8%)	5.0 (+0.7pt)	+62%	30.0
[Foreign exchange rates	s and impact]				
¥/US\$	¥83	¥98	+¥15 (yen	depreciation)
¥/Euro	¥107	¥129	+¥21 (yen	depreciation)
Impact on net sales	-	+¥85.2 bil.		_	
Impact on Op. income	-	+¥18.5 bil.	_		


Segment Forecasts for Fiscal 2014

(Billions of yen)	FY2013 Full-year (Results)	FY2014 Full-year (Current forecast)	YoY Change	YoY (%)	FY2014 Full-year (Previous forecast)
Medical	Net sales	394.7	490.0	+95.3	+24%	470.0
Weulcal	Op. income	87.1	110.0	+22.9	+26%	101.0
Life Science &	Net sales	85.5	100.0	+14.5	+17%	100.0
Industrial	Op. income	3.5	4.5	+1.0	+28%	7.0
	Net sales	107.6	104.0	-3.6	-3%	104.0
Imaging	Op. income	-23.1	-5.0	+18.1		-
Otherma	Net sales	41.7	26.0	-15.7	-38%	26.0
Others	Op. income	-4.9	-5.0	-0.1		-5.0
Elimination	Net sales	-	-	-	-	-
and corporate	Op. income	-29.3	-32.0	-2.7		-32.0
Consolidated	Net sales	743.9	720.0	-23.9	-3%	700.0
Total	Op. income	35.1	72.5	+37.4	+107%	71.0




Supplementary Materials

[Supplementary Materials] R&D Expenditures




* Figures exclude sales in the Information & Communication Business. 28


[Supplementary Materials] Depreciation and Amortization



[Supplementary Materials] Capital Expenditures




[Supplementary Materials] Digital Cameras




[Supplementary Materials] Interest-bearing Debt


(Billions of yen)




[Supplementary Materials] Equity Ratio



[Supplementary Materials] Performance Indices and Targets



[Supplementary Materials] Target (Consolidated)



Exchange rate assumptions: US\$1 = ¥90, 1 EUR = ¥120 (Note) The figures were released on May 15, 2013.

Supplementary Materials (By Segment)

	FY Ending March 2015	FY Ending March 2017
Medical	520 billion yen	650 billion yen
Life Science & Industrial	115 billion yen	135 billion yen
Imaging	100 billion yen	100 billion yen
Others	25 billion yen	35 billion yen
Total	760 billion yen	920 billion yen
Medical	111 billion yen	150 billion yen
Life Science & Industrial	9 billion yen	15 billion yen
Imaging	7 billion yen	9 billion yen
Others	-1 billion yen	1 billion yen
Elimination or Corporate	-33 billion yen	-32 billion yen
Total	93 billion yen	143 billion yen
	Life Science & Industrial Imaging Others Total Medical Life Science & Industrial Imaging Others Elimination or Corporate	Medical520 billion yenLife Science & Industrial115 billion yenImaging100 billion yenOthers25 billion yenTotal760 billion yenMedical111 billion yenLife Science & Industrial9 billion yenImaging7 billion yenElimination or Corporate-1 billion yen

Exchange rate assumptions: US\$1 = ¥90, 1 EUR = ¥120

(Note) The figures were released on May 15, 2013.



- This material contains forward-looking statements that reflect management's current views, plans and expectations. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause Olympus's actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by these forward-looking statements.
- Additionally, these information are subjected to change without notice in the future.
- Accordingly, Corporation wishes to caution readers that acutual results may differ materially from those projected in this material. Corporation assumes no responsibility for any damage resulting from the use of this material.